Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report-Reference-Cited by-同舟云学术

Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report

Published:2023-07 Issue:10399 Volume:402 Page:397-410
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Mohiuddin Muhammad M,Singh Avneesh K,Scobie Linda,Goerlich Corbin E,Grazioli Alison,Saharia Kapil,Crossan Claire,Burke Allen,Drachenberg Cinthia,Oguz Cihan,Zhang Tianshu,Lewis Billeta,Hershfeld Alena,Sentz Faith,Tatarov Ivan,Mudd Sarah,Braileanu Gheorghe,Rice Kathryn,Paolini John F,Bondensgaard Kent,Vaught Todd,Kuravi Kasinath,Sorrells Lori,Dandro Amy,Ayares David,Lau Christine,Griffith Bartley P

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months;Mohiuddin;Am J Transplant,2012

2. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft;Mohiuddin;Nat Commun,2016

3. Progressive genetic modifications of porcine cardiac xenografts extend survival to 9 months;Mohiuddin;Xenotransplantation,2022

4. Genetically modified porcine-to-human cardiac xenotransplantation;Griffith;N Engl J Med,2022

5. Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cells;Azimzadeh;Xenotransplantation,2014

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of Anti-CD40 and Anti-CD40L Antibodies as Co-Stimulation Blockade in Preclinical Cardiac Xenotransplantation;Biomedicines;2024-08-22

2. Research Highlights;Transplantation;2024-08-21

3. Harnessing the evolving CRISPR/Cas9 for precision oncology;Journal of Translational Medicine;2024-08-08

4. Xenotrasplante: ¿preparamos el futuro?;Nefrología;2024-08

5. Genetically engineered hypoimmunogenic cell therapy;Nature Reviews Bioengineering;2024-07-29